Anti-PD-1 or anti-PD-L1 drugs are currently recommended for cancer patients based on PD-L1 detection in tumor or immune cells via IHC, microsatellite instability (MSI) detection via polymerase chain reaction, or mismatch repair deficiency detection via IHC45. This evidence concerns the gene CD274 and neoplasm.